{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:03:33Z","timestamp":1778594613007,"version":"3.51.4"},"reference-count":30,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s240856","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:42:41Z","timestamp":1625791361000},"page":"3017-3026","source":"Crossref","is-referenced-by-count":48,"title":["Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-3139","authenticated-orcid":true,"given":"Autumn","family":"Walkerly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-0243","authenticated-orcid":true,"given":"Lauren D","family":"Leader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-009X","authenticated-orcid":true,"given":"Emily","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"VandenBerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"ref1","unstructured":"Center for Behavioral Health Statistics and Quality. 2019 National Survey on Drug Use and Health: Methodological Summary and Definitions. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2020."},{"key":"ref2","unstructured":"Center for Behavioral Health Statistics and Quality. 2017 National Survey on Drug Use and Health: Methodological Summary and Definitions. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018."},{"key":"ref3","unstructured":"National Comorbidity Survey (NSC). Harvard Medical School; 2007. Available from: https:\/\/www.hcp.med.harvard.edu\/ncs\/index.php.DataTable2:12-monthprevalenceDSM-IV\/WMH-CIDIdisordersbysexandcohort. Accessed March 27, 2021."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.30773\/pi.2019.0171","volume":"17","author":"Orsolini","year":"2020","journal-title":"Psychiatry Investig"},{"key":"ref5","volume-title":"Practice Guideline for the Treatment of Patients with Major Depressive Disorder","year":"2010"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40345-018-0133-9","volume":"6","author":"Gitlin","year":"2018","journal-title":"Int J Bipolar Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pnpbp.2013.09.005","volume":"48","author":"Bali","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.18758.1","volume":"8","author":"L\u00fcscher","year":"2019","journal-title":"F1000Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pneurobio.2013.09.003","volume":"113","author":"Schule","year":"2014","journal-title":"Prog Neurobiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/gbb.12321","volume":"16","author":"Stephens","year":"2017","journal-title":"Genes Brain and Behav"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00004850-199510030-00008","volume":"10","author":"Birkenh\u00e4ger","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/0006-3223(95)00049-7","volume":"38","author":"Petty","year":"1995","journal-title":"Biol Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/YIC.0000000000000316","volume":"35","author":"Lim","year":"2020","journal-title":"Int Clin Psychopharmacol"},{"key":"ref15","first-page":"18m12588","volume":"80","author":"Soric","year":"2019","journal-title":"J Clin Psych"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0706743716659417","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can J Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","volume":"60","author":"Botella","year":"2017","journal-title":"J Med Chem"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.psyneuen.2017.02.031","volume":"80","author":"Bixo","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"ref20","unstructured":"Sage Therapeutics, Inc. ZulressoTM (Brexanolone Infusion) [Package Insert]. Cambridge, MA: Sage Therapeutics, Inc; 2019."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1056\/NEJMoa1815981","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"N Engl J Med"},{"key":"ref24","unstructured":"Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder [Internet]. Cambridge: Businesswire; 2019. Available from: https:\/\/www.businesswire.com\/news\/home\/20191205005375\/en\/Sage-Therapeutics-Reports-Topline-Results-Pivotal-Phase. Accessed May 17, 2021."},{"key":"ref25","unstructured":"Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD [Internet]. Cambridge: sage Therapeutics; 2021. Available from: https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-positive-interim-topline-zuranolone. Accessed March 6, 2021."},{"key":"ref26","author":"Deligiannidis","year":"2020","journal-title":"Virtual"},{"key":"ref27","author":"Gunduz-Bruce","year":"2020","journal-title":"Virtual"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.15585\/mmwr.mm6919a2","volume":"69","author":"Bauman","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/01.AOG.0000183597.31630.db","volume":"106","author":"Gavin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"ref30","unstructured":"Zulresso REMS Training for Healthcare Settings [internet]. Sage Therapeutics, Inc.; 2020. Available from: https:\/\/www.zulressorems.com\/#Public\/Resources. Accessed March 1, 2021."}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71492","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:42:53Z","timestamp":1625791373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/review-of-allopregnanolone-agonist-therapy-for-the-treatment-of-depres-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2147\/dddt.s240856","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}